THE GLUTAMATE HYPOTHESIS OF
SCHIZOPHRENIA
Glutamate is the major excitatory
neurotransmitter in the brain . Phencyclidine and ketamine are noncompetitive
inhibitors of the NMDA receptor that exacerbate both cogni-tive impairment and
psychosis in patients with schizophrenia. PCP and a related drug, MK-801,
increase locomotor activity and, acutely or chronically, a variety of cognitive
impairments in rodents and primates. These effects are widely employed as a
means to develop novel antipsychotic and cognitive-enhancing drugs. Selective
5-HT2A antagonists, as well as atypical antipsy-chotic drugs, are
much more potent than D2 antagonists in blocking these effects of
PCP and MK-801. This was the starting point for the hypothesis that
hypofunction of NMDA receptors, located on GABAergic interneurons, leading to
diminished inhibitory influences on neuronal function, contributed to
schizophrenia. The diminished GABAergic activity can induce disinhibition of
downstream glutamatergic activity, which can lead to hyperstimulation of
cortical neurons through non-NMDA receptors. Preliminary evidence suggests that
LY2140023, a drug that acts as an agonist of the metabotropic 2/3 glutamate
receptor (mGLuR2/3), may be effective in schizophrenia.
The NMDA receptor, an ion channel, requires
glycine for full activation. It has been suggested that in patients with
schizophre-nia, the glycine site of the NMDA receptor is not fully saturated.
There have been several trials of high doses of glycine to promote
glutamatergic activity, but the results are far from convincing. Currently,
glycine transport inhibitors are in development as pos-sible antipsychotic
agents.
Ampakines are drugs that potentiate currents
mediated by AMPA-type glutamate receptors. In behavioral tests, ampakines are
effective in correcting behaviors in various animal models of schizophrenia and
depression. They protect neurons against neu-rotoxic insults, in part by
mobilizing growth factors such as brain-derived neurotrophic factor.
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2023 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.